Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363415 · ClinicalTrials.gov registry record · Phase 3
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 908
- Enrollment target
NCT00363415 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 908 participants.
The verdict
NCT00363415, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 908 participants
- Enrollment target
Study Summary
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.
Interventions
- DRUG carboplatin
- DRUG pemetrexed
- DRUG etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 908 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363415
The ClinicalTrials.gov registry entry for NCT00363415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 908 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00363415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363415 about?
NCT00363415 is a clinical study titled "Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer". This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will of...
What is the current status of trial NCT00363415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 908 participants. The study started on 2006-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00363415?
The interventions under investigation include: carboplatin (DRUG), pemetrexed (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT00363415?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.